- Home
- ATIF vs PRPO Comparison
ATIF vs PRPO Comparison
Compare ATIF & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIF
- PRPO
- Stock Information
- Founded
- ATIF 2015
- PRPO N/A
- Country
- ATIF United States
- PRPO United States
- Employees
- ATIF N/A
- PRPO N/A
- Industry
- ATIF Professional Services
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- ATIF Consumer Discretionary
- PRPO Industrials
- Exchange
- ATIF Nasdaq
- PRPO Nasdaq
- Market Cap
- ATIF 9.9M
- PRPO 9.5M
- IPO Year
- ATIF 2019
- PRPO N/A
- Fundamental
- Price
- ATIF $0.65
- PRPO $6.25
- Analyst Decision
- ATIF
- PRPO
- Analyst Count
- ATIF 0
- PRPO 0
- Target Price
- ATIF N/A
- PRPO N/A
- AVG Volume (30 Days)
- ATIF 22.3K
- PRPO 7.5K
- Earning Date
- ATIF 11-13-2024
- PRPO 11-06-2024
- Dividend Yield
- ATIF N/A
- PRPO N/A
- EPS Growth
- ATIF N/A
- PRPO N/A
- EPS
- ATIF N/A
- PRPO N/A
- Revenue
- ATIF $500,000.00
- PRPO $17,411,000.00
- Revenue This Year
- ATIF N/A
- PRPO $75.18
- Revenue Next Year
- ATIF N/A
- PRPO N/A
- P/E Ratio
- ATIF N/A
- PRPO N/A
- Revenue Growth
- ATIF N/A
- PRPO 31.31
- 52 Week Low
- ATIF $0.58
- PRPO $4.31
- 52 Week High
- ATIF $1.50
- PRPO $8.49
- Technical
- Relative Strength Index (RSI)
- ATIF 38.18
- PRPO 52.41
- Support Level
- ATIF $0.62
- PRPO $6.14
- Resistance Level
- ATIF $0.80
- PRPO $6.47
- Average True Range (ATR)
- ATIF 0.11
- PRPO 0.19
- MACD
- ATIF -0.02
- PRPO 0.01
- Stochastic Oscillator
- ATIF 4.76
- PRPO 88.00
About ATIF ATIF Holdings Limited
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.